Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells (original) (raw)

• Chiocca EA, Smith ER . Oncolytic viruses as novel anticancer agents: turning one scourge against another [In Process Citation]. Expert Opin Investig Drugs [MEDLINE record in process], 2000; 9: 311–327.
  Article PubMed Google Scholar
• Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [see comments]. Gene Therapy 2000; 7: 867–874.
  Article CAS PubMed Google Scholar
• Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859–866.
  Article CAS PubMed Google Scholar
• Whitley RJ . Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds.), Fields Virology, 3rd edn, Vol 2, pp 2297–2342. Lipincott-Raven: Philadelphia/New York, 1996.
  Google Scholar
• Carroll MC, Prodeus AP . Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10: 36–40.
  Article CAS PubMed Google Scholar
• Verschoor A, Brockman MA, Knipe DM, Carroll MC . Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 2001; 167: 2446–2451.
  Article CAS PubMed Google Scholar
• Da Costa XJ et al. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci USA 1999; 96: 12708–12712.
  Article CAS PubMed PubMed Central Google Scholar
• Siegal FP et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835–1837.
  Article CAS PubMed Google Scholar
• Kadowaki N, Antonenko S, Lau JY, Liu YJ . Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192: 219–226.
  Article CAS PubMed PubMed Central Google Scholar
• Bukowski JF, Morita CT, Brenner MB . Recognition and destruction of virus-infected cells by human gamma delta CTL. J Immunol 1994; 153: 5133–5140.
  CAS PubMed Google Scholar
• Johnson RM et al. A murine CD4-, CD8- T cell receptor-gamma delta T lymphocyte clone specific for herpes simplex virus glycoprotein I. J Immunol 1992; 148: 983–988.
  CAS PubMed Google Scholar
• Selin LK et al. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001; 166: 6784–6794.
  Article CAS PubMed Google Scholar
• Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR . Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 2002; 76: 2780–2788.
  Article CAS PubMed PubMed Central Google Scholar
• Fawaz LM, Sharif-Askari E, Menezes J . Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol 1999; 163: 4473–4480.
  CAS PubMed Google Scholar
• Fujioka N et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection viruses: a comparative study. J Virol 1999; 73: 2401–2409.
  CAS PubMed PubMed Central Google Scholar
• Feduchi E, Alonso MA, Carrasco L . Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63: 1354–1359.
  CAS PubMed PubMed Central Google Scholar
• Croen KD . Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993; 91: 2446–2452.
  Article CAS PubMed PubMed Central Google Scholar
• Ahmad A, Sharif-Askari E, Fawaz L, Menezes J . Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74: 7196–7203.
  Article CAS PubMed PubMed Central Google Scholar
• Karupiah G et al. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 261: 1445–1448.
  Article CAS PubMed Google Scholar
• Kodukula P et al. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162: 2895–2905.
  CAS PubMed Google Scholar
• Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.
  Article CAS PubMed Google Scholar
• Lubinski JM et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998; 72: 8257–8263.
  CAS PubMed PubMed Central Google Scholar
• Lubinski J et al. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC [published erratum appears in J Exp Med 2000 Feb 21;191(4):following 746]. J Exp Med 1999; 190: 1637–1646.
  Article CAS PubMed PubMed Central Google Scholar
• Costa J, Rabson AS, Yee C, Tralka TS . Immunoglobulin binding to herpes virus-induced Fc receptors inhibits virus growth. Nature 1977; 269: 251–252.
  Article CAS PubMed Google Scholar
• Dubin G et al. The role of herpes simplex virus glycoproteins in immune evasion. Curr Top Microbiol Immunol, 1992; 179: 111–120.
  CAS PubMed Google Scholar
• Friedman HM et al. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1 [In Process Citation]. J Immunol 2000; 165: 4528–4536 [MEDLINE record in process].
  Article CAS PubMed Google Scholar
• Friedman HM et al. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 1996; 70: 4253–4260.
  CAS PubMed PubMed Central Google Scholar
• Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–415.
  Article CAS PubMed Google Scholar
• Salio M, Cella M, Suter M, Lanzavecchia A . Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999; 29: 3245–3253.
  Article CAS PubMed Google Scholar
• Leib DA . Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr Top Microbiol Immunol 2002; 269: 171–185.
  CAS PubMed Google Scholar
• Suzutani T et al. The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection. J Gen Virol 2000; 81: 1763–1771.
  Article CAS PubMed Google Scholar
• Todo T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741–2755.
  Article CAS PubMed Google Scholar
• Song WC, Sarrias MR, Lambris JD . Complement and innate immunity. Immunopharmacology 2000; 49: 187–198.
  Article CAS PubMed Google Scholar
• Sastry K et al. Molecular characterization of the mouse mannose-binding proteins. The mannose-binding protein A but not C is an acute phase reactant. J Immunol 1991; 147: 692–697.
  CAS PubMed Google Scholar
• Kawasaki N, Kawasaki T, Yamashina I . Isolation and characterization of a mannan-binding protein from human serum.J Biochem (Tokyo) 1983; 94: 937–947.
  Article CAS Google Scholar
• Hansen S et al. Purification and characterization of two mannan-binding lectins from mouse serum. J Immunol 2000; 164: 2610–2618.
  Article CAS PubMed Google Scholar
• Haurum JS et al. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids 1993; 7: 1307–1313.
  Article CAS PubMed Google Scholar
• Smiley ML, Friedman HM . Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J Virol 1985; 55: 857–861.
  CAS PubMed PubMed Central Google Scholar
• Friedman HM et al. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates. J Virol 1986; 60: 470–475.
  CAS PubMed PubMed Central Google Scholar
• Schellingerhout D et al. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543–1549.
  Article CAS PubMed Google Scholar
• Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R . Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy 2000; 7: 1648–1655.
  Article CAS PubMed Google Scholar
• Yoon SS et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. Faseb J 2000; 14: 301–311.
  Article CAS PubMed Google Scholar
• Pawlik TM et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790–2795.
  CAS PubMed Google Scholar
• Nakamura H et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447–5452.
  CAS PubMed Google Scholar
• Nakamura et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109: 871–882.
  Article CAS PubMed PubMed Central Google Scholar
• Pawlik TM et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171–1181.
  Article CAS PubMed Google Scholar
• Neuwelt EA, Pagel MA, Dix RD . Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 1991; 74: 475–479.
  Article CAS PubMed Google Scholar
• Nilaver G et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood–brain barrier disruption. Proc Natl Acad Sci USA 1995; 92: 9829–9833.
  Article CAS PubMed PubMed Central Google Scholar
• Ikeda K et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881–887.
  Article CAS PubMed Google Scholar
• Wakimoto H et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275–282.
  Article CAS PubMed Google Scholar
• Ikeda K et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765–4775.
  Article CAS PubMed PubMed Central Google Scholar
• Welsh RM, O’Donnell CL, Reed DJ, Rother RP . Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72: 4650–4656.
  CAS PubMed PubMed Central Google Scholar
• Welsh Jr RM, Cooper NR, Jensen FC, Oldstone MB . Human serum lyses RNA tumour viruses. Nature 1975; 257: 612–614.
  Article CAS PubMed Google Scholar
• Agrawal RS et al. Complement and anti-alpha-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum. Gene Therapy 1999; 6: 146–148.
  Article CAS PubMed Google Scholar
• Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995; 182: 1345–1355.
  Article CAS PubMed Google Scholar
• Sokoloff AV et al. Specific recognition of protein carboxy-terminal sequences by natural IgM antibodies in normal serum. Mole Ther 2001; 3: 821–830.
  Article CAS Google Scholar
• Boes M et al. critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998; 188: 2381–2386.
  Article CAS PubMed PubMed Central Google Scholar
• Boes M et al. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 1998; 160: 4776–4787.
  CAS PubMed Google Scholar
• Yokota S et al. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology 2001; 286: 119–124.
  Article CAS PubMed Google Scholar
• He B, Gross M, Roizman B . The gamma(1)3.45 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843–848.
  Article CAS PubMed PubMed Central Google Scholar
• Leib DA et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999; 189: 663–672.
  Article CAS PubMed PubMed Central Google Scholar
• Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR . NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 2000; 20: 1278–1290.
  Article CAS PubMed PubMed Central Google Scholar
• Deb A et al. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 2001; 166: 6170–6180.
  Article CAS PubMed Google Scholar
• Uetani K et al. Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide synthase. J Immunol 2000; 165: 988–996.
  Article CAS PubMed Google Scholar
• Geiger KD et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 1997; 238: 189–197.
  Article CAS PubMed Google Scholar
• Bsibsi M, Ravid R, Gveric D, van Noort JM . Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013–1021.
  Article CAS PubMed Google Scholar
• Lindsberg PJ et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 1996; 40: 587–596.
  Article CAS PubMed Google Scholar
• Shinoura N et al. G. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 1994; 86: 143–149.
  Article CAS PubMed Google Scholar
• Maenpaa A et al. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996; 148: 1139–1152.
  CAS PubMed PubMed Central Google Scholar
• Todo T et al. Viral shedding and biodistribution of G207, a multimutated conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588–595 [Record as supplied by publisher].
  Article CAS PubMed Google Scholar
• Miller CG, Fraser NW . Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000; 60: 5714–5722.
  CAS PubMed Google Scholar
• Delman KA et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy [In Process Citation]. Hum Gene Ther 2000; 11: 2465–2472 [MEDLINE record in process].
  Article CAS PubMed Google Scholar
• Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Therapy 1999; 6: 1751–1758.
  Article CAS PubMed Google Scholar
• Huemer HP et al. Herpes simplex virus binds to human serum lipoprotein. Intervirology 1988; 29: 68–76.
  CAS PubMed Google Scholar
• Srinivas RV et al. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 1990; 176: 48–57.
  Article CAS PubMed Google Scholar
• Srinivas RV et al. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J Cell Biochem 1991; 45: 224–237.
  Article CAS PubMed Google Scholar
• Ash RJ . Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells. Virology 1986; 155: 584–592.
  Article CAS PubMed Google Scholar
• Thormar H et al. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob Agents Chemother 1987; 31: 27–31.
  Article CAS PubMed PubMed Central Google Scholar
• Johansson PJ, Kjellen L . Inhibition of herpes simplex virus growth caused by preparations of animal immunoglobulins is not dependent on Fc–Fc receptor interactions. Intervirology 1988; 29: 334–338.
  CAS PubMed Google Scholar
• Goodbourn S, Didcock L, Randall RE . Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81: 2341–2364.
  Article CAS PubMed Google Scholar
• Benencia F, Courreges MC . Nitric oxide and macrophage antiviral extrinsic activity. Immunology 1999; 98: 363–370.
  Article CAS PubMed PubMed Central Google Scholar
• Goldstein DJ, Weller SK, An ICP6: lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988; 62: 2970–2977.
  CAS PubMed PubMed Central Google Scholar